Director at Jyong Biotech (MENS) discloses holding 3,000 shares

Rhea-AI Filing Summary

Jyong Biotech Ltd. director Hsu Feng-Lin filed an initial ownership report showing holdings of the company’s common stock. The filing lists direct beneficial ownership of 3,000 shares of Common Stock following the reported entry, providing a baseline of this director’s equity position in the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hsu Feng-Lin

Role Director

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,000 shares (Direct)

Footnotes (1)

Key Figures

Common Stock held: 3,000 shares

1 metrics

Common Stock held 3,000 shares Total shares beneficially owned following Form 3 entry

Key Terms

Form 3, beneficial ownership, Common Stock

3 terms

Form 3 regulatory

"Initial statement of beneficial ownership filed on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"Initial statement of beneficial ownership of securities by insider"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Common Stock financial

"Security title reported as Common Stock of Jyong Biotech Ltd."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hsu Feng-Lin

(Last) (First) (Middle)

23F-3, NO.95, SEC. 1, XINTAI 5TH RD.

(Street)

NEW TAIPEI CITY TAIWAN, PROVINCE OF CHINA 221

(City) (State) (Zip)

TAIWAN

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
Jyong Biotech Ltd. [ MENS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Hsu Feng-Lin	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Jyong Biotech (MENS) Form 3 filing show for Hsu Feng-Lin?

The Form 3 filing shows that director Hsu Feng-Lin directly holds 3,000 shares of Common Stock in Jyong Biotech Ltd. This initial ownership statement establishes the director’s reported equity position with the company as of the filing date.

How many Jyong Biotech (MENS) shares does Hsu Feng-Lin own?

Hsu Feng-Lin is reported as directly owning 3,000 shares of Common Stock in Jyong Biotech Ltd. This figure reflects total shares beneficially owned following the reported entry in the Form 3 insider ownership statement.

What is the purpose of this Jyong Biotech (MENS) Form 3?

This Form 3 serves as an initial statement of beneficial ownership by director Hsu Feng-Lin in Jyong Biotech Ltd. It records that the director holds 3,000 common shares, giving investors visibility into the insider’s equity stake.

Is the Jyong Biotech (MENS) Form 3 a buy or sell transaction?

The Form 3 for Jyong Biotech Ltd. does not report a specific buy or sell transaction. Instead, it records that director Hsu Feng-Lin beneficially owns 3,000 shares of Common Stock following the reported entry.

What type of security is reported in the Jyong Biotech (MENS) Form 3?

The Form 3 reports holdings of Common Stock of Jyong Biotech Ltd. Director Hsu Feng-Lin is shown as directly owning 3,000 common shares, reflecting the insider’s equity stake in the company at the time of the filing.